Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies
Zhenfeng Zhang, Stephan Urban
Journal of Hepatology (2020) Vol. 74, Iss. 3, pp. 686-699
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
Stephan Urban, Christoph Neumann‐Haefelin, Pietro Lampertico
Gut (2021) Vol. 70, Iss. 9, pp. 1782-1794
Open Access | Times Cited: 174
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 1, pp. 117-129
Closed Access | Times Cited: 98
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
Tarik Asselah, Vladimir Chulanov, Pietro Lampertico, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 2, pp. 133-143
Closed Access | Times Cited: 23
Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome
Fabien Zoulim, Pei‐Jer Chen, Maura Dandri, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 6, pp. 1087-1099
Open Access | Times Cited: 16
Response‐guided long‐term treatment of chronic hepatitis D patients with bulevirtide—results of a “real world” study
Mathias Jachs, Caroline Schwarz, Marlene Panzer, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 1, pp. 144-154
Open Access | Times Cited: 60
Interferon‐based treatment of chronic hepatitis D
Lisa Sandmann, Heiner Wedemeyer
Liver International (2022) Vol. 43, Iss. S1, pp. 69-79
Open Access | Times Cited: 43
Viral hepatitis: Milestones, unresolved issues, and future goals
Pietro Torre, Andrea Aglitti, Mario Masarone, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 28, pp. 4603-4638
Open Access | Times Cited: 42
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta
Julius Hollnberger, Yang Liu, Simin Xu, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 657-665
Closed Access | Times Cited: 18
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA
Katja Deterding, Cheng‐Jian Xu, Kerstin Port, et al.
Journal of Viral Hepatitis (2023) Vol. 30, Iss. 7, pp. 597-606
Open Access | Times Cited: 13
Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis
Mathias Jachs, Teresa Binter, Caroline Schmidbauer, et al.
United European Gastroenterology Journal (2021) Vol. 9, Iss. 10, pp. 1119-1127
Open Access | Times Cited: 27
Hepatitis Delta Infection: A Clinical Review
Brian L. Pearlman
Seminars in Liver Disease (2023) Vol. 43, Iss. 03, pp. 293-304
Open Access | Times Cited: 11
Advances and Challenges in Managing Hepatitis D Virus: Evolving Strategies
Harish Gopalakrishna, Maria Mironova, Harel Dahari, et al.
Current Hepatology Reports (2024) Vol. 23, Iss. 1, pp. 32-44
Open Access | Times Cited: 4
A bibliometric analysis of the hepatitis D virus and its therapeutic options
Taslima Nasrin, Mehboob Hoque, Safdar Ali
Discover Viruses. (2025) Vol. 2, Iss. 1
Open Access
Single cell analysis of mature hepatocytes reveals an IRF1 driven restriction of HDV infection.
Frauke Lange, Jonathan Garn, Matthias Bruhn, et al.
JHEP Reports (2025), pp. 101429-101429
Open Access
Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro
Hirofumi Ohashi, Feng Wang, Frank Stappenbeck, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 3163-3163
Open Access | Times Cited: 24
Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition
Maura Dandri, Antonio Bertoletti, Marc Lütgehetmann
Seminars in Immunopathology (2021) Vol. 43, Iss. 4, pp. 535-548
Open Access | Times Cited: 24
Circular RNA ITCH: An Emerging Multifunctional Regulator
Kaixin Su, Yi Qiao, Xiaohan Dai, et al.
Biomolecules (2022) Vol. 12, Iss. 3, pp. 359-359
Open Access | Times Cited: 17
Multiple Regions Drive Hepatitis Delta Virus Proliferation and Are Therapeutic Targets
Jun Zi, Xiuzhu Gao, Juan Du, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 13
Treatment of Chronic Hepatitis D with Bulevirtide—A Fight against Two Foes—An Update
Péter Ferenci, Thomas Reiberger, Mathias Jachs
Cells (2022) Vol. 11, Iss. 22, pp. 3531-3531
Open Access | Times Cited: 13
Mechanism of action and treatment of type I interferon in hepatocellular carcinoma
Chunxiu Peng, Zhijian Ye, Ying Ju, et al.
Clinical & Translational Oncology (2023) Vol. 26, Iss. 2, pp. 326-337
Closed Access | Times Cited: 7
Underestimated Prevalence of HIV, Hepatitis B Virus (HBV), and Hepatitis D Virus (HDV) Triple Infection Globally: Systematic Review and Meta-analysis
Sisi Chen, Feng Ren, Xiaojie Huang, et al.
JMIR Public Health and Surveillance (2022) Vol. 8, Iss. 11, pp. e37016-e37016
Open Access | Times Cited: 12
Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients
L Scheller, Gudrun Hilgard, Olympia E. Anastasiou, et al.
Medicine (2021) Vol. 100, Iss. 28, pp. e26571-e26571
Open Access | Times Cited: 15
Natural history of untreated HDV patients: Always a progressive disease?
Habiba Kamal, Soo Aleman
Liver International (2022) Vol. 43, Iss. S1, pp. 5-21
Open Access | Times Cited: 10
Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies
Laura A. Novotny, J.G. Evans, Lishan Su, et al.
Viruses (2021) Vol. 13, Iss. 6, pp. 1090-1090
Open Access | Times Cited: 13
The hepatitis delta virus and chronic hepatitis D
Maura Dandri, Annika Volmari, Marc Lütgehetmann
Journal of Hepatology (2022) Vol. 77, Iss. 5, pp. 1448-1450
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top